TODD STRATEGY GROUP for NOVARTIS, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIC BERGREN | Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker |
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| NICOLAS MAGALLANES | Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
| NICHOLAS UEHLECKE | Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee |
Medicare/Medicaid MMM
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIC BERGREN | — |
| PAUL EDATTEL | — |
| NICOLAS MAGALLANES | — |
| DANIEL M TODD | — |
| NICHOLAS UEHLECKE | — |
Trade (domestic/foreign) TRD
Tariffs.
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novaitis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIC BERGREN | — |
| PAUL EDATTEL | — |
| NICOLAS MAGALLANES | — |
| DANIEL M TODD | — |
| NICHOLAS UEHLECKE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.